This conclusion was supported by decreased distant metastasis-free survival times of patients with high expression levels of ADAM12-L, increased EGFR phosphorylation in a mouse xenograft model of breast cancer, and a strong correlation between the level of anti-ADAM12-L and anti-phospho-EGFR immunostaining in human breast tumor samples. Here, EGFR is linked to breast neoplasm.